Other languages PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
3.61 ^USD	+7.76%		+11.08%	-27.36%

28/03	B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating	MT
27/03	Empire Metals targets key milestones in Australia	AN

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Empire Metals targets key milestones in Australia	28/03
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
PDS Biotechnology Corporation Announces Publication of Preclinical Research	13/03
PDS Biotechnology Corporation Announces Executive Changes	23/01
Apyx Medical Names Matthew Hill as CFO	28/11
PDS Biotechnology Appoints Lars Boesgaard as Finance Chief	28/11
PDS Biotechnology Corporation Announces Resignation of Matthew Hill as Principal Financial Officer and Principal Accounting Officer, Effective December 1, 2023	28/11
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
NetScientific's portfolio company updates on cancer trial	10/11
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	09/11
NetScientific investee claims promising results in biomarker study	24/23/24
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO	23/23/23
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	11/23/11
NetScientific portfolio company updates on cancer trial	03/23/03
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA	03/23/03
PDS Biotechnology Investigational Vaccine Shows 'Active Neutralization' of Multiple Influenza Viruses in Preclinical Studies	20/23/20
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies	20/23/20
NetScientific's PDS suffers wider loss as R&D costs mount	15/23/15
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Other languages

Filters